 (OR)
and 95% conÔ¨Ådence intervals (CIs). This document provided evidence that TEVAR reduced the risk of mortality
in both intact (OR, 0.6; 95% CI, 0.36-0.99) and ruptured
(OR, 0.58; 95% CI, 0.38-0.88) settings. In addition, paraplegia risks and pulmonary